Investor's Business Daily on MSN
Dianthus Therapeutics has appreciated 12-fold over two years. What's going on?
Dianthus Therapeutics stock shot higher Monday after the company said it would advance its experimental CIDP treatment.
The 12-16-week open-label study evaluated Ruxoprubart as monotherapy in treatment-naïve PNH patients. Key findings include: CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- NovelMed Therapeutics Inc., a ...
Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants ...
Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Key objectives achieved: ...
Morning Overview on MSN
Single DMT dose eased depression-like symptoms in mice, study finds
A single injection of N,N-dimethyltryptamine, the psychedelic compound found in ayahuasca, reversed depression-like symptoms in chronically stressed mice, according to a peer-reviewed study published ...
When an AI system in health care gives a confident answer, should clinicians trust it? In a new article from Frontiers in ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果